uniQure N.V.

QURE

NL0010696654

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 08:00:00 14/01/26 am AEDT			5-day change	1st Jan Change
21.50 ^USD	-6.68%		-3.63%	-10.15%

10/01	UniQure Climbs on Scheduling FDA Meeting for Huntington's Disease Treatment	DJ
10/01	Sector Update: Health Care Stocks Rise Pre-Bell Friday	MT

US-listed shares of uniQure rise 13% premarket as FDA review talks revive hopes for Huntington's therapy

Published on 01/10/2026 at 12:10 am AEDT

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about uniQure N.V.

10/01	UniQure Climbs on Scheduling FDA Meeting for Huntington's Disease Treatment	DJ
10/01	Sector Update: Health Care Stocks Rise Pre-Bell Friday	MT
10/01	US-listed shares of uniQure rise 13% premarket as FDA review talks revive hopes for Huntington's therapy	RE
09/01	UniQure Sets US FDA Meeting to Discuss Application for Investigational Huntington's Gene Therapy	MT
16/12	Top Premarket Gainers	MT
05/12	Wall Street Cautious as Key Inflation Report Looms, Driving Muted Premarket Action for US Equity Futures	MT
05/12	UniQure Shares Drop After More Negative News From FDA on Huntington's Disease Drug	DJ
04/12	Top Premarket Decliners	MT
04/12	UniQure Seeks US FDA Follow-Up Meeting After Being Told Data Do Not Support BLA Submission	MT
04/12	Uniqure N.V. Provides Regulatory Update on Amt-130 for Huntington's Disease	CI
25/11	Certain Performance Stock of uniQure N.V. are subject to a Lock-Up Agreement Ending on 25-NOV-2025.	CI
25/11	Certain Restricted Stock of uniQure N.V. are subject to a Lock-Up Agreement Ending on 25-NOV-2025.	CI
25/11	Certain Options of uniQure N.V. are subject to a Lock-Up Agreement Ending on 25-NOV-2025.	CI
25/11	Certain Ordinary Shares of uniQure N.V. are subject to a Lock-Up Agreement Ending on 25-NOV-2025.	CI
11/11	UniQure N.V., Q3 2025 Earnings Call, Nov 10, 2025
11/11	UniQure N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
10/11	UniQure's Q3 Net Loss Widens, Revenue Increases	MT
10/11	Earnings Flash (QURE) UniQure Posts Q3 Net Loss $1.38 a Share, vs. FactSet Est of $0.90 Loss	MT
10/11	Earnings Flash (QURE) uniQure N.V. Reports Q3 Revenue $3.7M, vs. FactSet Est of $5.8M	MT
07/11	Uniqure Insider Sold Shares Worth $1,177,517, According to a Recent SEC Filing	MT
05/11	Chardan Cuts Price Target on uniQure to $53 From $76, Keeps Buy Rating	MT
05/11	RBC Cuts Price Target on uniQure to $45 From $65, Keeps Outperform, Speculative Risk	MT
05/11	William Blair Downgrades uniQure N.V to Market Perform From Outperform	MT
04/11	Top Midday Decliners	MT
04/11	UniQure Shares Fall Sharply as Trading Resumes After Volatility Halt	MT

Uniqure NV is a company based in the Netherlands specialized in gene therapy. It seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. It develops, both internally and through partnerships, a pipeline of gene therapies. It produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Companyâs lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntingtonâs disease is in Phase I/II clinical study.

Employees

209

Sector

Biotechnology & Medical Research

Calendar

02/03 - Q4 2025 Earnings Release (Projected)

More about the company